ReviewThe Lancet. Global health2021
Operation Warp Speed: implications for global vaccine security.
Review in The Lancet. Global health, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 55 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
55 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- The effects on clinical trial activity of direct funding and taxation policy interventions made by government: A systematic review.PloS one · 2022Pooled it
- Is there a difference in the efficacy of COVID-19 vaccine in males and females? - A systematic review and meta-analysis.Human vaccines & immunotherapeutics · 2021Pooled it
- Planning for the future of the American Society for Microbiology's Health Unit by the Council on Microbial Sciences.mSphere · 2026Review
- A pan-beta-coronavirus vaccine bearing conserved and asymptomatic B- and T-cell epitopes protects against highly pathogenic Delta and highly transmissible Omicron SARS-CoV-2 variants.Human vaccines & immunotherapeutics · 2025Article
- Article
- Accelerated vaccine process development by orthogonal protein characterization.Scientific reports · 2025Article
- Modeling the impact of early vaccination in an influenza pandemic in the United States.NPJ vaccines · 2025Article
- States, global power and access to medicines: a comparative case study of China, India and the United States, 2000-2019.Globalization and health · 2025Article
- Factors Predicting COVID-19 Vaccine Effectiveness and Longevity of Humoral Immune Responses.Vaccines · 2024Review
- A comparative analysis of supply chain factors impacting COVID-19 vaccine security in high-income countries (HICs) and low-income and middle-income countries (LMICs).BMJ global health · 2024Article
- Vaccine Science Diplomacy and "The Phenomenon of Man".The Linacre quarterly · 2024Article
- Review
- Design and Development of an Antigen Test for SARS-CoV-2 Nucleocapsid Protein to Validate the Viral Quality Assurance Panels.Viruses · 2024Article
- Article
- The Israeli health system's rapid responses during the COVID-19 pandemic.Israel journal of health policy research · 2024Article
- Can the Revolution in mRNA-Based Vaccine Technologies Solve the Intractable Health Issues of Current Ruminant Production Systems?Vaccines · 2024Review
- Political Prioritization of Access to Medicines and Right to Health: Need for an Effective Global Health Governance Through Global Health Diplomacy Comment on "More Pain, More Gain! The Delivery of COVID-19 Vaccines and the Pharmaceutical Industry's Role in Widening the Access Gap".International journal of health policy and management · 2024Article
- Designing the global vaccine supply chain: balancing intellectual property rights with post COVID-19 vaccine equity.BMJ global health · 2023Review
- Innovative approaches to COVID-19 medical countermeasure development.The Journal of antimicrobial chemotherapy · 2023Review
- A critical analysis of COVAX alliance and corresponding global health governance and policy issues: a scoping review.BMJ global health · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Several global efforts are underway to develop COVID-19 vaccines, and interim analyses from phase 3 clinical testing have been announced by nine organisations: Pfizer, the Gamaleya Research Institute of Epidemiology and Microbiology, Moderna, AstraZeneca, Sinopharm Group, Sinovac Biotech, Johnson & Johnson, Novavax, and CanSino Biologics. The US programme known as Operation Warp Speed provided US$18 billion in funding for development of vaccines that were intended for US populations. Depending on safety and efficacy, vaccines can become available through mechanisms for emergency use, expanded access with informed consent, or full licensure. An important question is: how will these Operation Warp Speed vaccines be used for COVID-19 prevention in global health settings? We address some key questions that arise in the transition from US to global vaccine prevention efforts and from ethical and logistical issues to those that are relevant to global vaccine security, justice, equity, and diplomacy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.